Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
Abstract Background Clinical evidence of immune checkpoint inhibitors combined with antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was limited. Recombinant human endostatin (rh‐endostatin), an antiangiogenic drug, and camrelizumab, an anti‐PD‐1 antibody, have been...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5526 |
| _version_ | 1827958714112409600 |
|---|---|
| author | Xingxiang Pu QianZhi Wang Liyu Liu Bolin Chen Kang Li Yu Zhou Zengmei Sheng Ping Liu Yucheng Tang Li Xu Jia Li Yi Kong Fang Xu Yan Xu Lin Wu |
| author_facet | Xingxiang Pu QianZhi Wang Liyu Liu Bolin Chen Kang Li Yu Zhou Zengmei Sheng Ping Liu Yucheng Tang Li Xu Jia Li Yi Kong Fang Xu Yan Xu Lin Wu |
| author_sort | Xingxiang Pu |
| collection | DOAJ |
| description | Abstract Background Clinical evidence of immune checkpoint inhibitors combined with antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was limited. Recombinant human endostatin (rh‐endostatin), an antiangiogenic drug, and camrelizumab, an anti‐PD‐1 antibody, have been approved for the treatment of advanced NSCLC in China. This study aimed to investigate the efficacy and safety of rh‐endostatin plus camrelizumab and chemotherapy in the treatment of advanced NSCLC. Methods Eligible patients were enrolled and received camrelizumab (200 mg, day 1) every 3 weeks and continuous intravenous infusion of rh‐endostatin (70 mg/day, days 1–3) and cisplatin combined with pemetrexed (for adenocarcinoma) or paclitaxel (for NSCLC other than adenocarcinoma) every 3 weeks. Primary endpoint was progression‐free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profiles. Results Overall, 27 patients were included, and 25 patients were eligible for efficacy evaluation. For these 25 patients, ORR was 48.15% (13/27) and DCR was 85.19% (23/27). With a median follow‐up of 10.37 months, the median PFS was 8.9 (95% CI: 4.23–13.57) months. Median OS was not reached. Overall, 96.3% of patients experienced at least one treatment‐related adverse event, and grade 3 TRAEs occurred in 9 (33.3%) patients. No unexpected AEs were observed. Conclusion Rh‐endostatin plus camrelizumab and chemotherapy showed favorable efficacy and safety profile in patients with advanced NSCLC, representing a promising treatment regimen for these patients. |
| first_indexed | 2024-04-09T15:40:43Z |
| format | Article |
| id | doaj.art-40863fc0695948cdbd48b2cb12683261 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T15:40:43Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-40863fc0695948cdbd48b2cb126832612023-04-27T10:12:43ZengWileyCancer Medicine2045-76342023-04-011277724773310.1002/cam4.5526Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective studyXingxiang Pu0QianZhi Wang1Liyu Liu2Bolin Chen3Kang Li4Yu Zhou5Zengmei Sheng6Ping Liu7Yucheng Tang8Li Xu9Jia Li10Yi Kong11Fang Xu12Yan Xu13Lin Wu14Department of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Oncology The Third Hospital of Changsha Changsha ChinaDepartment of Respiratory The First Hospital of Changsha Changsha ChinaDepartment of Oncology Hengyang Central Hospital/the affiliated Hengyang Hospital of Southern Medical University Hengyang ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha ChinaAbstract Background Clinical evidence of immune checkpoint inhibitors combined with antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was limited. Recombinant human endostatin (rh‐endostatin), an antiangiogenic drug, and camrelizumab, an anti‐PD‐1 antibody, have been approved for the treatment of advanced NSCLC in China. This study aimed to investigate the efficacy and safety of rh‐endostatin plus camrelizumab and chemotherapy in the treatment of advanced NSCLC. Methods Eligible patients were enrolled and received camrelizumab (200 mg, day 1) every 3 weeks and continuous intravenous infusion of rh‐endostatin (70 mg/day, days 1–3) and cisplatin combined with pemetrexed (for adenocarcinoma) or paclitaxel (for NSCLC other than adenocarcinoma) every 3 weeks. Primary endpoint was progression‐free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profiles. Results Overall, 27 patients were included, and 25 patients were eligible for efficacy evaluation. For these 25 patients, ORR was 48.15% (13/27) and DCR was 85.19% (23/27). With a median follow‐up of 10.37 months, the median PFS was 8.9 (95% CI: 4.23–13.57) months. Median OS was not reached. Overall, 96.3% of patients experienced at least one treatment‐related adverse event, and grade 3 TRAEs occurred in 9 (33.3%) patients. No unexpected AEs were observed. Conclusion Rh‐endostatin plus camrelizumab and chemotherapy showed favorable efficacy and safety profile in patients with advanced NSCLC, representing a promising treatment regimen for these patients.https://doi.org/10.1002/cam4.5526anti‐angiogenesiscamrelizumabimmune checkpoint inhibitorsnon‐small cell lung cancerrecombinant human endostatin |
| spellingShingle | Xingxiang Pu QianZhi Wang Liyu Liu Bolin Chen Kang Li Yu Zhou Zengmei Sheng Ping Liu Yucheng Tang Li Xu Jia Li Yi Kong Fang Xu Yan Xu Lin Wu Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study Cancer Medicine anti‐angiogenesis camrelizumab immune checkpoint inhibitors non‐small cell lung cancer recombinant human endostatin |
| title | Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study |
| title_full | Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study |
| title_fullStr | Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study |
| title_full_unstemmed | Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study |
| title_short | Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study |
| title_sort | rh endostatin plus camrelizumab and chemotherapy in first line treatment of advanced non small cell lung cancer a multicenter retrospective study |
| topic | anti‐angiogenesis camrelizumab immune checkpoint inhibitors non‐small cell lung cancer recombinant human endostatin |
| url | https://doi.org/10.1002/cam4.5526 |
| work_keys_str_mv | AT xingxiangpu rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT qianzhiwang rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT liyuliu rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT bolinchen rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT kangli rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT yuzhou rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT zengmeisheng rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT pingliu rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT yuchengtang rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT lixu rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT jiali rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT yikong rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT fangxu rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT yanxu rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy AT linwu rhendostatinpluscamrelizumabandchemotherapyinfirstlinetreatmentofadvancednonsmallcelllungcanceramulticenterretrospectivestudy |